AXA Framlington Biotech R Acc USD
|Bid Price||-||Offer Price||-|
|Mid Price||USX 102.30||Day Change||USX -0.40 (-0.15%)|
|Price Date||24 May 2017||Crown Rating|
|Shares Class||Inc.||Yield||0.00 %|
|Total Expense Ratio||0.00||Fund Size||531,100,000.00|
|Launch Date||26/11/2001||Standard Initial Charge (%)||5.50|
|Annual Management Charge (%)||1.75||Sector||IMA UK Equity Income|
|Min Investment (£)||1,000.00||Total Expense Ratio (%)||0.00|
|ISIN||GB00BZ3T0190||Min TopUp (£)||100.00|
The aim of this Fund is to provide long-term capital growth.
Linden Thomson joined AXA IM in June 2011 as sector specialist on the Healthcare equity desk. Linden joined AXA IM from Hedge Fund Clear River Capital where she was responsible for fundamental stock research across the global pharmaceutical and biotechnology sectors. Prior to that she worked for Goldman Sachs on the sell side where she was based in the healthcare research team with specific focus on the biotechnology sector. She graduated from Edinburgh University with a BSc in Medical Microbiology and is a CFA Charterholder.